Notch signaling pathway in tumor immune microenvironment
Roles of Notch signaling pathway in tumor immune microenvironment. Notch signaling can affect the activity of various immune cells within tumor microenvironment. Notch signaling suppresses PMN-MDSC production and induces MDSC expansion, contributing to tumor immunosuppression. Intriguingly, PMN-MDSCs can elicit Jag/Notch signal transduction pathway in cancer cell. The crosstalk between cancer cells and PMN-MDSCs finally enhances cancer metastasis. Notch signaling play dual roles in regulating T cell-mediated immune responses in cancer. Notch pathway can affect TAM recruitment and polarization. Cancer cells trigger the activation of Notch signaling in endothelial cells, which mediates the education of TAMs by cancer cells. This leads to formation of immunosuppressive microenvironment and impairment of T cell-mediated immunity. Notch activation reduces the intratumoral infiltration of NK cells, while it has opposite effects on Treg frequency and activity. Notch signaling leads to IL-17-driven inflammation via Th17 recruitment. Notch signaling mediates the communication between cancer cells and CAFs. On one hand, activated Notch pathway in CAFs causes compromised antitumor immunity and supports cancer development. On the other hand, increased activity of Notch pathway in CAFs can inhibit cancer progression. Cancer cells attract neutrophils into tumor microenvironment and motivate Notch signaling in recruited neutrophils. Notch-activated neutrophils suppress the cytotoxic activity of CD8+ T cells. Notch signaling fosters DC terminal differentiation and drives antigen cross-presentation to CD8+ T cells. Consequently, Notch-primed DCs retard cancer progression. Notch mutation is associated with a decline in B cell population in tumor microenvironment. Furthermore, Notch activation upregulates immune checkpoints (PD-1 and PD-L1) to blunt adaptive antitumor immunity. MDSC, myeloid-derived suppressor cell; Dlls, Delta-like ligands; PMN-MDSC, polymorphonuclear-myeloid-derived suppressor cell; PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1; DC, dendritic cell; Jags, Jaggeds; CAF, cancer-associated fibroblast; Th17, T helper 17; Treg cell, regulatory T cell; NK cell, natural killer cell; TAMs, tumor-associated macrophages